A 42-year-old man with a 10-year history of hepatitis B (HBeAg-positive, HBV DNA 6 × 10^5 IU/mL) and compensated cirrhosis (Child-Pugh A) presents for routine follow-up. He has no prior treatment. Ultrasound shows no features of hepatocellular carcinoma. What is the most appropriate next step in management?

Explanation

## Clinical Context **Key Point:** This patient has HBeAg-positive chronic hepatitis B with cirrhosis (even if compensated) and high viral load (HBV DNA >10^5 IU/mL). Cirrhosis is an absolute indication for antiviral therapy, regardless of ALT level or HBeAg status. ## Indications for Antiviral Therapy in Chronic Hepatitis B ### Treatment Criteria (AASLD / EASL Guidelines) Antiviral therapy is indicated in ANY of the following: 1. **Cirrhosis** (compensated or decompensated) — treat ALL patients 2. **HBeAg-positive** with HBV DNA ≥10^5 IU/mL AND ALT >1× ULN 3. **HBeAg-negative** with HBV DNA ≥10^4 IU/mL AND ALT >1× ULN 4. **HBV DNA ≥10^8 IU/mL** (regardless of HBeAg or ALT) 5. **Decompensated cirrhosis** — treat immediately **High-Yield:** Cirrhosis = treat, regardless of other parameters. This patient meets criterion #1. ### First-Line Antiviral Agents | Agent | Class | Barrier to Resistance | Renal Clearance | Preferred in Cirrhosis? | |-------|-------|----------------------|------------------|------------------------| | Tenofovir | Nucleotide RT inhibitor | High | Yes (adjust) | **Yes** | | Entecavir | Nucleoside RT inhibitor | High | Yes | **Yes** | | Lamivudine | Nucleoside RT inhibitor | Low | No | No (high resistance) | | Interferon-α | Immunomodulator | — | — | No (contraindicated in cirrhosis) | **Clinical Pearl:** Tenofovir and entecavir are preferred in cirrhosis because they have high genetic barriers to resistance and are effective at suppressing HBV DNA. Interferon is contraindicated in cirrhosis due to risk of decompensation. ## Why This Patient Needs Treatment NOW 1. **Cirrhosis present** — even if compensated (Child-Pugh A), cirrhosis is an absolute indication 2. **High viral load** — HBV DNA 6 × 10^5 IU/mL (>10^5) increases risk of HCC and disease progression 3. **HBeAg-positive** — indicates active viral replication 4. **Goal:** Suppress HBV DNA to <20 IU/mL to prevent further fibrosis, HCC, and decompensation **Mnemonic: TREAT Cirrhosis — T (Tenofovir/nucleotide), R (RNA/DNA high), E (Every patient), A (Antiviral), T (Therapy)** ## Why Other Options Are Incorrect | Option | Why Wrong | |--------|----------| | Liver biopsy | Cirrhosis is already clinically/radiologically evident; biopsy is not needed for diagnosis and carries risk in cirrhotic patients; does not change management (treatment is indicated regardless) | | Interferon-α | Contraindicated in cirrhosis due to risk of decompensation, infection, and cytopenias; nucleoside/nucleotide inhibitors are preferred | | Observe without treatment | Cirrhosis is an absolute indication for treatment; observation allows continued viral replication, fibrosis progression, and HCC risk; not acceptable management | [cite:Harrison 21e Ch 297; AASLD Hepatitis B Guidance]